MRNS

Marinus Pharmaceuticals, Inc.

No insider bought or sold Marinus Pharmaceuticals, Inc. in the last 12 months

$0Bought, 12 mo

$0Sold, 12 mo

Follow MRNS

MRNS over the last year

Prices for MRNS aren't in yet.

MRNS after insider buys

3 months after each buy, from the first price a copier could get.

No buys have 3 months of prices yet. A record shows here at 3.

Every filing

19 insider filings since 2016, newest first

MRNSSell

Joseph Hulihan · Chief Medical Officer

$28K−4.0%Feb 21

MRNSSell

Steven Pfanstiel · CFO and COO

$31K−4.0%Feb 21

MRNSSell

Scott Braunstein · Chair and CEO

$118K−5.0%Feb 21

MRNSSell

Scott Braunstein · Chair and CEO

$62K−4.0%Aug 8

MRNSSell

Steven Pfanstiel · CFO and COO

$27K−5.0%Aug 8

MRNSSell

Joseph Hulihan · Chief Medical Officer

$28K−6.0%Aug 8

MRNSSell

Nicole Vitullo · Director

$67K−54.0%Mar 16

MRNSSell

Edward F Smith · Former VP, CFO, Treasurer

$718K−75.0%Mar 11

MRNSBuy

Scott Braunstein · CEO

Edward F Smith · CFO

Christopher Michael Cashman · CEO

$25K−3.0%Jan 30

MRNSSell

Christopher Michael Cashman · CEO

$60K−4.0%Jan 22

MRNSSell

Bain Capital Life Sciences Investors, LLC · 10% owner

$10.0M−24.0%Dec 19

MRNSSell

Anand Mehra · 10% owner

$1.0M−98.0%Oct 24

MRNSSell

Canaan VII LP · 10% owner

$224K−7.0%Aug 9

MRNSSell

Canaan VII LP · 10% owner

$218K−7.0%Aug 5

MRNSSell

Canaan VII LP · 10% owner

$42K−1.0%Aug 2

MRNSSell

Canaan VII LP · 10% owner

$37K−1.0%Jul 27

MRNSSell

Canaan VII LP · 10% owner

$514K−11.0%Jul 26

Filings come from SEC EDGAR and prices from daily closes. Not investment advice.